Funding Opportunities

NIH Funding Opportunities

Notice of Change in the Key Dates for Administrative Supplements for U.S. - Brazil Biomedical Collaborative Research, PA-14-328
Notice NOT-AI-14-070 from the NIH Guide for Grants and Contracts
Fri, 19 Sep 2014 12:59:47 EST

Notice of Pre-application Webinar for RFA-CA-14-018 "Pediatric Preclinical Testing Consortium: Research Programs (U01)" and RFA-CA-14-019 "Pediatric Preclinical Testing Consortium: Coordinating Center (U01)"
Notice NOT-CA-14-047 from the NIH Guide for Grants and Contracts
Thu, 18 Sep 2014 08:21:45 EST

Erratum to RFA-CA-14-012 "Cancer Intervention and Surveillance Modeling Network (CISNET) (U01)"
Notice NOT-CA-14-056 from the NIH Guide for Grants and Contracts
Fri, 19 Sep 2014 12:04:32 EST

Notice of Early Expiration of PAR-12-222 "Cohort Studies of HIV/AIDS and Substance Use (U01)"
Notice NOT-DA-14-046 from the NIH Guide for Grants and Contracts
Wed, 17 Sep 2014 03:57:05 EST

Notice of Pre-application Teleconferences for RFA-DK-14-004 and RFA-DK-14-018 "Prevention of Lower Urinary Tract Symptoms in Women: Bladder Health" Initiatives
Notice NOT-DK-14-024 from the NIH Guide for Grants and Contracts
Mon, 15 Sep 2014 12:09:03 EST

Notice of Change in Due Date for PAR-13-390 "Indo-US Collaborative Program on Affordable Medical Devices (R03)"
Notice NOT-EB-14-007 from the NIH Guide for Grants and Contracts
Thu, 18 Sep 2014 01:34:52 EST

Notice of Intent to Publish Funding Opportunity Announcement for Environmental Influences during Windows of Susceptibility in Breast Cancer Risk (U01)
Notice NOT-ES-14-010 from the NIH Guide for Grants and Contracts
Mon, 15 Sep 2014 12:04:02 EST

Notice of Intent to Publish Funding Opportunity Announcement for Coordinating Center for the Breast Cancer and the Environment Research Program (U01)
Notice NOT-ES-14-011 from the NIH Guide for Grants and Contracts
Mon, 15 Sep 2014 12:05:59 EST

Notice of NINDS's Participation in RFA-MH-15-800 "Consortium on Biomarker and Outcome Measures of Social Impairment for Use in Clinical Trials in Autism Spectrum Disorder (U19)"
Notice NOT-NS-14-045 from the NIH Guide for Grants and Contracts
Tue, 16 Sep 2014 08:32:50 EST

Notice to Extend the Expiration Date of PAR-12-072 "NINDS Exploratory Clinical Trials for Small Business (STTR [R42])"
Notice NOT-NS-14-049 from the NIH Guide for Grants and Contracts
Thu, 18 Sep 2014 11:49:47 EST

Notice to Extend the Expiration Date of PAR-12-073 "NINDS Exploratory Clinical Trials for Small Business (SBIR [R44])"
Notice NOT-NS-14-050 from the NIH Guide for Grants and Contracts
Thu, 18 Sep 2014 12:12:19 EST

Notice of Correction to PA-14-335 "Advancing Interventions to Improve Medication Adherence (R21)"
Notice NOT-OD-14-131 from the NIH Guide for Grants and Contracts
Wed, 17 Sep 2014 12:37:15 EST

Clarification of Allowed Subaward/Consortium Costs for PAR-13-245 "Mentored Research Scientist Development Award (K01)"
Notice NOT-OH-14-014 from the NIH Guide for Grants and Contracts
Tue, 16 Sep 2014 08:15:45 EST

Clarification of Allowed Subaward/Consortium Costs for PAR-13-129 "Occupational Safety and Health Research (R01)"
Notice NOT-OH-14-015 from the NIH Guide for Grants and Contracts
Tue, 16 Sep 2014 08:27:13 EST

Resubmission Applications Allowed for PAR-14-175 "Agricultural, Forestry and Fishing Safety and Health Research (U01)"
Notice NOT-OH-14-016 from the NIH Guide for Grants and Contracts
Wed, 17 Sep 2014 01:50:33 EST

Notice of Change in the Application Due Date in RFA-TR-14-009 "Clinical and Translational Science Award (U54)"
Notice NOT-TR-14-012 from the NIH Guide for Grants and Contracts
Thu, 18 Sep 2014 09:15:22 EST

Analyses of Datasets on Older Populations with High Prevalence of Mobility Disability to Develop Clinically Meaningful Diagnostic Cut-Points for Low Muscle Mass and/or Low Muscle Strength (U01)
Funding Opportunity RFA-AG-15-013 from the NIH Guide for Grants and Contracts. This initiative invites applications for support of analyses of existing data (or data whose collection will be completed by one year from the date of this FOA) from older populations with high prevalence of mobility disability, low muscle mass, and low muscle strength (weakness). Interventions targeted at low muscle mass and/or weakness may prevent or reduce mobility disability in some older persons. To assess the efficacy of such interventions against mobility disability, there is a need to test them in persons in whom muscle mass and/or strength are (or will be) sufficiently low to be likely contributors to disability. Thus there is a need for evidence-based diagnostic cut-points to define target populations for treatments. Applications submitted in response to this FOA should support development and evaluation of diagnostic cut-points based on analyses of relations of mobility disability to muscle mass and strength. These analyses should extend and expand upon analyses to date on this topic, which have identified and proposed cut-points for low muscle mass and weakness. Studies supported through this FOA should clarify relations between muscle mass and strength, impaired physical function, and mobility disability, and their implications for setting diagnostic cut-points, through analyses of data from populations with substantially more individuals with mobility disability than were included in previous analyses. Applicants are encouraged to consider combining datasets from multiple populations that contain information on all of the following: at least one objective measure of muscle mass at the same anatomic site(s) common to all included studies, at least one direct measure of muscle strength common to included data sets, gait speed, and self-reported mobility status in populations of older adults. Analyses of relations to other measures of strength, muscle power, and physical performance (e.g., Short Physical Performance Battery), and mobility disability are encouraged.
Tue, 16 Sep 2014 03:50:02 EST

Consortium on Biomarker and Outcome Measures of Social Impairment for Use in Clinical Trials in Autism Spectrum Disorder (U19)
Funding Opportunity RFA-MH-15-800 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Consortium on Biomarkers and Outcome Measures of Social Impairment in Autism Spectrum Disorder (ASD) in order to generate objective tools for use in clinical trials of behavioral or pharmacologic interventions. The FOA will support a Consortium project to conduct a multi-site study to assess a well-justified set of standardized lab-based measures of domains of social impairment and biological measures (resting state and task-based EEG as well as eye tracking measures) that show promise in school age individuals with ASD at baseline, 6 and 24 week time points. The intent of the FOA is to qualify a set of measures that can be used as stratification biomarkers and/or as sensitive and reliable objective measures of social impairment in ASD clinical trials. A key goal of the Consortium projectis to provide a community resource for broad sharing of all data generated including processed/analyzed data, with rapid and timely deposition of data into the National Database for Autism Research (NDAR). All data generated in this project are expected to be deposited in NDAR and will be accessible for use by all qualified investigators. In addition, blood (DNA) samples are expected to be deposited in the NIMH Repository and Genomics Resource for future research use. The Consortium project will assess the following: (1) whether lab-based measures of specific domains of social impairment in ASD are more sensitive indicators of clinical status compared to commonly used clinician and caregiver assessments of social impairment for their potential use as outcome measures in clinical trials; (2) whether eye-tracking, electrophysiological (EEG) paradigms, or a combination of the two, have potential utility as stratification biomarkers and/or as sensitive and reliable measures of change in ASD clinical trials; (3) the relationship (correlation) of lab-based measures of domains of social impairment to eye tracking or EEG (resting state and task-based) paradigms; and (4) the relationship (correlation) of lab-based measures of domains of social impairment to commonly used clinician and caregiver assessments of social impairment. In addition, the FOA includes a resource aim for the collection of blood (DNA) samples from all subjects, including the parents of ASD subjects, for future genomic analyses.
Mon, 15 Sep 2014 08:38:52 EST

Self-Management for Health in Chronic Conditions (R21)
Funding Opportunity PA-14-343 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to support research in self-management focused across conditions. A recent report from the Institute of Medicine (IOM) identifies the epidemic of chronic condition as the nations leading health challenge and calls for cross-cutting, coordinated public health actions for living well with chronic illness. This Funding Opportunity Announcement (FOA) addresses that recommendation by describing an initiative that focuses on self-management as a mainstream science in order to reduce the burden of chronic illnesses/conditions. Self-management is the ability of the individual, in conjunction with family, community, and healthcare professionals, to manage symptoms, treatments, lifestyle changes, and psychosocial, cultural, and spiritual consequences associated with a chronic illness or condition.
Fri, 19 Sep 2014 10:10:18 EST

Self-Management for Health in Chronic Conditions (R01)
Funding Opportunity PA-14-344 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to support research in self-management focused across conditions. A recent report from the Institute of Medicine (IOM) identifies the epidemic of chronic condition as the nations leading health challenge and calls for cross-cutting, coordinated public health actions for living well with chronic illness. This Funding Opportunity Announcement (FOA) addresses that recommendation by describing an initiative that focuses on self-management as a mainstream science in order to reduce the burden of chronic illnesses/conditions. Self-management is the ability of the individual, in conjunction with family, community, and healthcare professionals, to manage symptoms, treatments, lifestyle changes, and psychosocial, cultural, and spiritual consequences associated with a chronic illness or condition.
Fri, 19 Sep 2014 09:49:04 EST

Self-Management for Health in Chronic Conditions (R15)
Funding Opportunity PA-14-345 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to support research in self-management focused across conditions. A recent report from the Institute of Medicine (IOM) identifies the epidemic of chronic condition as the nations leading health challenge and calls for cross-cutting, coordinated public health actions for living well with chronic illness. This Funding Opportunity Announcement (FOA) addresses that recommendation by describing an initiative that focuses on self-management as a mainstream science in order to reduce the burden of chronic illnesses/conditions. Self-management is the ability of the individual, in conjunction with family, community, and healthcare professionals, to manage symptoms, treatments, lifestyle changes, and psychosocial, cultural, and spiritual consequences associated with a chronic illness or condition.
Fri, 19 Sep 2014 10:26:06 EST

NIDCR Behavioral or Social Intervention Clinical Trial Planning Grant (R34)
Funding Opportunity PAR-14-342 from the NIH Guide for Grants and Contracts. The NIDCR will support R34 grants for the planning and design of clinical studies to test behavioral or social interventions related to its mission (for details, please see: http://www.nidcr.nih.gov/Research/DER/bssrb.htm). The R34 grant will support activities that include, but are not limited to: the development of the behavioral or social intervention manual and procedures for training interventionists; development of the clinical protocol that will guide a subsequent clinical trial; the tools for data management, participant safety and operational oversight; and other activities to prepare for a subsequent clinical trial. R34 applications preparing for a behavioral or social intervention study may involve human subjects as part of small-scale testing of the feasibility and acceptability of the intervention(s), measures, methods, training approaches, etc. However, the R34 planning grant is not meant to support efficacy testing of interventions.
Fri, 19 Sep 2014 10:55:49 EST

NIDCR Clinical Trial or Biomarker Clinical Validation Study Planning Grant (R34)
Funding Opportunity PAR-14-346 from the NIH Guide for Grants and Contracts. The NIDCR will support R34 grants for the planning and design of clinical trials or biomarker clinical validation studies. This Funding Opportunity Announcement (FOA) will support activities to develop: the draft clinical protocol; the Clinical Investigators Brochure (or equivalent) if needed; tools for data and quality management, safety and operational oversight plans; recruitment and retention strategies; the study team; and other essential documents such as a draft Manual of Procedures that are necessary for the subsequent clinical trial or biomarker clinical validation study. The Clinical Trial or Biomarker Clinical Validation Study Planning Grant is not designed for the collection of preliminary data on the efficacy of the intervention (clinical or pre-clinical), or the collection of prospective data to support the rationale for a clinical trial or study. Evaluation of the potential subject population to determine its eligibility for participation in the future trial or biomarker validation study is allowed but not required. Planning grant activities for behavioral and social interventions may include pilot testing of the intervention during the R34 phase, thus a separate FOA (PAR-14-342) will support these types of interventional trials.
Fri, 19 Sep 2014 12:30:49 EST